These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Hiramatsu K; Aritaka N; Hanaki H; Kawasaki S; Hosoda Y; Hori S; Fukuchi Y; Kobayashi I Lancet; 1997 Dec; 350(9092):1670-3. PubMed ID: 9400512 [TBL] [Abstract][Full Text] [Related]
4. Genotype analysis of methicillin-resistant Staphylococcus aureus with and without reduced susceptibility to vancomycin using pulsed-field gel electrophoresis. Furuya D; Yagihashi A; Uehara N; Yajima T; Kobayashi D; Watanabe N Infect Control Hosp Epidemiol; 2001 Sep; 22(9):536-8. PubMed ID: 11732780 [No Abstract] [Full Text] [Related]
6. Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan, 1996. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 1997 Jul; 46(27):624-6. PubMed ID: 9218648 [TBL] [Abstract][Full Text] [Related]
7. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Khosrovaneh A; Riederer K; Saeed S; Tabriz MS; Shah AR; Hanna MM; Sharma M; Johnson LB; Fakih MG; Khatib R Clin Infect Dis; 2004 May; 38(9):1328-30. PubMed ID: 15127350 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore. Sng LH; Koh TH; Wang GC; Hsu LY; Kapi M; Hiramatsu K Int J Antimicrob Agents; 2005 Feb; 25(2):177-9. PubMed ID: 15664490 [No Abstract] [Full Text] [Related]
16. [Determination of the in vitro activity of 2 glycopeptides (vancomycin and teicoplanin) against methicillin-resistant Staphylococcus aureus of intrahospital origin]. Gil M; Otth L; Wilson M; Arce E; Zaror A; Lizama V Rev Med Chil; 2000 Jan; 128(1):111-2. PubMed ID: 10883531 [No Abstract] [Full Text] [Related]
17. Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin? Chambers HF; Hegde SS Expert Rev Anti Infect Ther; 2007 Jun; 5(3):333-5. PubMed ID: 17547497 [No Abstract] [Full Text] [Related]
18. Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus. Wootton M; Walsh TR; MacGowan AP Antimicrob Agents Chemother; 2005 Sep; 49(9):3982-3. PubMed ID: 16127089 [No Abstract] [Full Text] [Related]
19. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469 [TBL] [Abstract][Full Text] [Related]
20. In-vitro activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibilities to vancomycin. Tanaka M; Wada N; Kurosaka SM; Chiba M; Sato K; Hiramatsu K J Antimicrob Chemother; 1998 Oct; 42(4):552-3. PubMed ID: 9818762 [No Abstract] [Full Text] [Related] [Next] [New Search]